Full-Time

Sales Associate

Updated on 7/21/2026

ENOVIS

ENOVIS

1,001-5,000 employees

Global medical technology company; orthopedic solutions

No salary listed

No H1B Sponsorship

Salem, OR, USA + 1 more

More locations: Corvallis, OR, USA

In Person

Relocation within Oregon may be required; travel up to 75% with overnight stays.

Category
Retail (1)
Required Skills
Sales
Inventory Management

Get referred to ENOVIS

Find people who can refer or advise you

Requirements
  • Bachelor’s degree in business, Marketing, or related healthcare field required
  • Must possess a valid Driver’s License and current automobile insurance
  • Must be able to relocate in the specified geography upon assignment to Territory Manager role
  • Must be willing to remain in the Sales Associate role for a minimum of one year
Responsibilities
  • Partners with the Territory Manager in all aspects of the sales call pattern, including but not limited to, covering clinics in the assigned territory, promotion of the products in assigned accounts, managing inventory, and, as he/she learns and grows, beginning to convert customers to DJO
  • Sales Support: Partners with the Territory Manager and organization to meet and exceed business targets (quotas)
  • Sales Support: Serves as the primary backup contact for Territory Manager
  • Sales Support: Responsible for keeping the Territory Manager informed of all sales related activity, market trends, and competitor activity within the territory
  • Sales Activity: Assists Territory Manager in identifying and qualifying potential sales leads
  • Sales Activity: Introduces the Company’s products to potential customers
  • Sales Activity: Cultivates customer relationships by initiating contact with physicians, clinic staff, and other device users
  • Sales Activity: Partners with Territory Manager on inventory management and building of proper inventory levels and sets to meet customer needs
  • Product Knowledge: Following product training, tailors DJO’s promotional message based upon knowledge of the customer, advises on appropriate product selection, answers customer questions about product functionality and distinguishes DJO products from those of DJO’s competitors
  • Product Knowledge: Provides product education on technical and clinical aspects of products to customers, prospective customers and patients
  • Product Knowledge: Measures, fits, and troubleshoots DJO products including custom braces
  • Product Knowledge: Assists with equipment delivery, set-up, follow-up, and service as needed
  • Administrative: Coordinates, prepares, gathers and submits accurate paperwork required for insurance billing in a timely manner
  • Compliance: Demonstrates commitment to the DJO Compliance & Ethics Program, the DJO Code of Conduct, the DJO Sales and Marketing Code of Conduct, the AdvaMed Code of Ethics, and all supporting and applicable regulations, policies and procedures
  • Compliance: Treats Protected Health Information (PHI) with the strictest confidentiality in accordance with HIPAA standards
  • Compliance: Acquires a basic understanding of the field to include regulatory compliance issues and adhere to these guidelines
  • Compliance: Other duties as assigned
Desired Qualifications
  • Minimum of 2 years of healthcare industry experience in customer service or sales related area preferred
  • Orthopedic therapeutic device training preferred
  • Knowledge of healthcare reimbursement preferred. Knowledge of orthopedic therapeutic devices and their application preferred

Enovis develops medical devices and services to improve patient outcomes and restore mobility. It operates Prevention & Recovery with orthopedic braces, soft goods, vascular therapy, compression garments, and hot/cold therapy, and Reconstructive with joint implants and surgical tools such as Novastep. It differentiates itself through a broad clinically oriented portfolio, a global footprint, and the EGX continuous improvement program, plus the LimaCorporate acquisition expanding its transatlantic reach. Its goal is to provide better patient outcomes and mobility worldwide through sustained growth and operational excellence.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

2022

Get referred to ENOVIS

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Extremities segment grew 10% organically in Q1 2026, driven by double-digit shoulder growth and Nebula uptake.
  • Strong 2026 earnings forecast of $3.52–$3.73 per share exceeded analyst projections, triggering a 12.6% stock jump.
  • LimaCorporate acquisition in 2024 strengthened Enovis's transatlantic orthopedic implant portfolio in the reconstructive segment.

What critics are saying

  • $1.18B goodwill impairment and negative TTM earnings of $1.37B risk covenant breaches if Nebula cash flow fails by Q3 2026.
  • Stryker and Zimmer Biomet's established robot platforms threaten 10% extremities growth within 6–12 months with high impact.
  • Medicare reimbursement for bone growth stimulators may recur after 2025, threatening $589M Q1 2026 revenue stability.

What makes ENOVIS unique

  • Enovis combines rigid bracing with breathable design in the Spinamic scoliosis brace to boost teen compliance.
  • The ARVIS shoulder robot enables augmented reverse glenoid procedures with continued global adoption targeted in 2026.
  • CT-RevitL delivers precise veterinary photobiomodulation therapy using COMPASS technology to reduce treatment variability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Legal Services

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

32%
Enovis
Jun 15th, 2026
Colfax Corporation Announces Closing of Initial Public Offering - Enovis

The Investor Relations website contains information about Enovis's business for stockholders, potential investors, and financial analysts.

Yahoo Finance
Feb 28th, 2026
Enovis reports strong revenue growth and new device uptake despite $1.18B goodwill impairment

Enovis Corporation has reported strong organic revenue growth driven by new product launches, including the Nebula Stem and OrthoDrive Impactor, which have seen rapid market uptake. The medical technology company's devices are gaining traction with surgeons and hospitals. However, Enovis recorded a significant goodwill impairment charge in its fourth quarter and full-year results, affecting its balance sheet. The impairment raises questions about returns from previous acquisitions and future capital allocation strategy. Trading at $25.47, Enovis shares are approximately 44% below the analyst price target of $45.18. The company currently shows a loss of $1.18 billion and trades at a forward price-to-earnings ratio of 25.73 times. Investors are advised to monitor how product adoption and procedure volumes affect future cash flow.

Yahoo Finance
Feb 26th, 2026
Enovis stock jumps 12.6% on strong 2026 earnings forecast despite Q4 revenue miss

Enovis Corporation shares jumped 12.6% in morning trading after the medical technology company reported mixed fourth-quarter results but issued a strong earnings forecast for 2026. Whilst quarterly revenue of approximately $576 million missed expectations, adjusted earnings per share of $0.95 beat analyst estimates. The stock surge was driven by Enovis's 2026 earnings guidance of $3.52 to $3.73 per share, with the midpoint significantly exceeding analyst projections. This positive profit outlook overshadowed the revenue shortfall. Enovis shares have experienced high volatility, with 26 moves exceeding 5% over the past year. The stock is down 6.6% year-to-date and trading 38.1% below its 52-week high of $40 from March 2025.

Yahoo Finance
Feb 26th, 2026
Enovis reports $520.6M Q4 loss despite adjusted earnings of 95 cents per share

Enovis Corporation reported a fourth-quarter loss of $520.6 million, or $9.10 per share. The Wilmington, Delaware-based manufacturing and engineering company posted adjusted earnings of 95 cents per share, excluding asset impairment and non-recurring costs. Revenue for the quarter reached $575.8 million. For the full year, Enovis reported a loss of $1.18 billion, or $20.75 per share, on revenue of $2.25 billion.

Yahoo Finance
Jan 23rd, 2026
BTIG initiates Enovis with $41 target as orthopedic tech firm eyes growth from new product launches

Enovis Corporation has received positive analyst coverage, with BTIG initiating a Buy rating and $41 price target on 6 January. The orthopedic care company is expected to see accelerated growth in 2026 driven by new product launches across extremities, hips and knees. BTIG highlighted the company's consistent mid-to-high single-digit organic revenue growth in its Reconstruction and Prevention & Recovery segments. The higher-growth Reconstruction business is expected to drive margins whilst the mature Prevention & Recovery segment delivers steady cash flow. UBS maintained its Buy rating but lowered its price target to $50 from $57, projecting sales of $2.26 billion in 2025, $2.37 billion in 2026 and $2.52 billion in 2027.